Tamar Taddei, MD
Professor of Internal Medicine (Digestive Diseases)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Vice Chief, Faculty Development, Digestive Diseases
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Vice Chief, Faculty Development, Digestive Diseases
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Vice Chief, Faculty Development, Digestive Diseases
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
About
Titles
Professor of Internal Medicine (Digestive Diseases)
Vice Chief, Faculty Development, Digestive Diseases
Positions outside Yale
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Biography
Dr. Taddei is Chief of Gastroenterology at VA Connecticut Healthcare System and Professor of Medicine (Digestive Diseases) and Vice Chief of Faculty Development (Digestive Diseases) at Yale School of Medicine. Her clinical interests focus on developing systems and programs to deliver outstanding multidisciplinary care to people with liver cancer. She directs the Liver Cancer Program at VA Connecticut Healthcare System and founded a VA regional tumor board serving Connecticut, Massachusetts, Rhode Island, and Vermont. Her research focuses on outcomes and clinical trials in cirrhosis and liver cancer. She is co-principal investigator of the Veterans Outcomes and Costs Associated with Liver disease (VOCAL) study group, the Statins and Cirrhosis - Reducing Events of Decompensation (SACRED) clinical trial, and the PREventing Liver Cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM) clinical trial. Passionate about educating, mentoring and sponsoring the next generation, Dr. Taddei has been recognized with teaching awards for her dedication to the education and career advancement of medical students, residents, and fellows.
Appointments
Digestive Diseases
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Digestive Diseases
- Hepatology
- Internal Medicine
- Liver Center
- Lysosomal Disease & Inherited Metabolic Liver Disease Program
- Status of Women in Medicine Committee (SWIM)
- Viral Hepatitis Program
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
Education & Training
- Fellow
- Yale University School of Medicine (2007)
- Resident
- Georgetown University Hospital (2004)
- MD
- Georgetown University School of Medicine (2000)
- BS
- Georgetown University (1992)
Research
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0002-6500-1739
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Rajni Mehta, MPH
Amy Justice, MD, PhD
Dhanpat Jain, MD
Catherine Mezzacappa, MD, MPH
Mario Strazzabosco, MD, PhD
Pramod Mistry, MBBS, PhD, MA, MD
Liver Cirrhosis
Carcinoma, Hepatocellular
Delivery of Health Care
Digestive System Diseases
Publications
2024
Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities and Outcomes.
Serper M, Pulaski M, Zhang S, Taddei T, Kaplan D, Mahmud N. Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities and Outcomes. The American Journal Of Gastroenterology 2024 PMID: 39530516, DOI: 10.14309/ajg.0000000000003190.Peer-Reviewed Original ResearchAltmetricConceptsFactors associated with useVeterans Health AdministrationMitigate healthcare disparitiesAlbumin useAssociated with lower in-hospital mortalityLower in-hospital mortalityCare variationHealthcare disparitiesNephrology consultationRetrospective cohort studyHealth AdministrationIn-hospital mortalityCohort studyVeteransEvaluate trendsCTP class BLiver disease sodiumSpontaneous bacterial peritonitisAKI stage 1ConsultationSBPCTP-ADisparitiesIntravenous albuminBacterial peritonitisRisk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitisA Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System
Haque L, Tate J, Chew M, Caniglia E, Taddei T, Re V. A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System. Pharmacoepidemiology And Drug Safety 2024, 33: e70024. PMID: 39477692, DOI: 10.1002/pds.70024.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsVeterans Health Administration dataHealth administrative dataAdministrative dataElectronic health record systemsHealth record systemsInternational Classification of DiseasesCoding algorithmOutpatient International Classification of DiseasesPositive predictive valueClassification of DiseasesHepatic decompensationDiagnosis codesPharmacoepidemiologic researchMedical recordsVeteransRecording systemValidation algorithmAlgorithmChronic liver diseaseDecompensationLiver diseasePredictive valueRecordsDiagnosisClinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes
Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal Of Clinical Pathology 2024, aqae136. PMID: 39418121, DOI: 10.1093/ajcp/aqae136.Peer-Reviewed Original ResearchConceptsSH-HCCSteatohepatitic hepatocellular carcinomaHepatocellular carcinomaLiver diseaseHepatitis C virus infectionC virus infectionStage of fibrosisPresence of steatohepatitisOverall survivalHistological subtypesPrognostic factorsHCC subtypesBackground liverHCC casesClinicopathological featuresConventional HCCHistopathological patternsHyaline globulesTumor cellsMallory-Denk bodiesGlycogenated nucleiSteatotic liver diseaseHCCSurvival analysisSteatohepatitisA Crisis in Scope: Recruitment and Retention Challenges Reported by VA Gastroenterology Section Chiefs.
von Rosenvinge E, Vela S, Paine E, Chang M, Hanson B, Taddei T, Smalley W, Dunbar K, Khan N, Kahng L, Anwar J, Zing R, Gawron A, Dominitz J, Baffy G. A Crisis in Scope: Recruitment and Retention Challenges Reported by VA Gastroenterology Section Chiefs. Federal Practitioner 2024, 41: 256-260. PMID: 39410921, PMCID: PMC11473028, DOI: 10.12788/fp.0504.Peer-Reviewed Original ResearchConceptsBarriers to recruitmentHuman resource challengesVeterans AffairsUS Department of Veterans AffairsDepartment of Veterans AffairsAdministrative burdenBarriers to retentionHealth of veteransVA Medical CenterSection chiefsLow salariesResource challengesRetention challengesMedical specialtiesSupport staffReducing administrative burdensMedical CenterStaffing supportUS DepartmentBurdenDigestive healthCurrent vacanciesSecond-mostRecruitmentSalarySevere Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceThe Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes.
Wang R, Serper M, Taddei T, Kaplan D, Mahmud N. The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes. The American Journal Of Gastroenterology 2024 PMID: 39051649, DOI: 10.14309/ajg.0000000000002976.Peer-Reviewed Original ResearchAltmetricConceptsAssociated with hepatic decompensationAngiotensin-converting enzyme inhibitorsAssociated with reduced mortalityAngiotensin receptor blockersACE-I/ARBConverting enzyme inhibitorsCV-related mortalityHepatocellular carcinomaHepatic decompensationCox regressionAngiotensin receptor blocker exposureEnzyme inhibitorsVeterans Health AdministrationCalcium channel blockersSubsets of patientsChronic liver diseaseCause-specific hazard modelInverse probability treatmentIdentified new initiatorsOutcome of mortalityNew initiativesCirrhosis decompensationCompensated cirrhosisDecompensated cirrhosisChannel blockersW31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
Haque L, Fiellin D, Bryant K, Edelman E, Justice A, Lim J, Re V, Marshall B, Taddei T, Tate J, Tetrault J, Williams E, McGinnis K. W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis. Drug And Alcohol Dependence 2024, 260: 110649. DOI: 10.1016/j.drugalcdep.2023.110649.Peer-Reviewed Original ResearchScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosisIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reports
Academic Achievements & Community Involvement
honor Alvan R. Feinstein Award
Yale School of Medicine AwardYale School of MedicineDetails05/22/2017United Stateshonor Digestive Diseases Fellowship Teaching Award
Yale University AwardYale University School of Medicine, Section of Digestive DiseasesDetails06/21/2011United Stateshonor Best Teacher – YNHH Hospitalist Service
Yale University AwardYale-New Haven HospitalDetails12/01/2010United Stateshonor Samuel Kushlan Award for Clinical Excellence in Fellowship
Yale University AwardYale UniversityDetails06/30/2007United States
Clinical Care
Overview
Tamar H. Taddei, MD, cares for patients with digestive and liver diseases, including transplant recipients and patients with liver cancer. “As a clinician, it is extremely gratifying to be able to make a difference in an individual's life,” she says. In addition to managing her own clinical practice, Dr. Taddei directs liver cancer roundtable meetings, where practitioners take a team-based approach to providing the best care strategy at Smilow Cancer Hospital at Yale New Haven, and at the VA Connecticut Healthcare System in West Haven.
A professor of medicine (digestive diseases) at Yale School of Medicine and Chief of Gastroenterology at VA Connecticut Healthcare System, Dr. Taddei focuses her research on improving outcomes for patients with liver ailments and on early detection of liver tumors. “The field is interesting, dynamic and challenging,” she says. “The liver is an amazing organ.”
She is excited by effective drugs for hepatitis C which have cured many patients and reduced the risk of cirrhosis and liver cancer, but she is concerned with the growing incidence of fatty liver. “We need to focus on wellness—healthy diet and exercise—before we become ill,” she says.
Clinical Specialties
Board Certifications
Transplant Hepatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2010
Gastroenterology
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2017
- Original Certification Date
- 2007
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- November 08, 2024
Liver Cancer Screening: A New Tool for Improved Detection
- September 10, 2024
Liver Cancer Screening Post-Hep C Cure Improves Survival
- July 29, 2024
Dr. Tamar Taddei on Yale Cancer Answers: Multidisciplinary Liver Cancer Care
- April 29, 2024
Dr. Tamar Taddei on Yale Cancer Answers
Get In Touch
Contacts
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.